10 likes | 150 Views
Results From Adding Recombinant LH In Normoresponder Patients For Assisted Reproductive Technology Treatment: A Prospective Randomized Control Trial Mohseni F. 1 ,Dehghani Firouzabadi R. 1 ,Yari N. 1 ,Etebary S. 1
E N D
Results From Adding Recombinant LH In Normoresponder Patients For Assisted Reproductive Technology Treatment: A Prospective Randomized Control Trial Mohseni F. 1 ,Dehghani Firouzabadi R. 1,Yari N. 1,Etebary S. 1 1Research and clinical center for infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran Objective Results Based on classical two cell– two-gonadotropin theory, in the follicle, FSH and LH put on their main effects on the granulosa and theca cells. LH is essential for androgens production. Androgens as precursor, is used for estradiol production by granulosa cells under aromatase activity. Profound suppression of LH concentrations in some normogonadotropic patients can cause several adverse effects. In ART cycles, women undergoing ovarian stimulation can experience sever LH deficiency following oversuppression of endogenous pituitary secretion due to GnRH analogues suppression. The mean of age in group 1 was 31.35 and in group 2 were 31.85. In group 2 the number of retrieved oocytes, mature oocytes, cleaved embryos, transferred embryos, estradiol levels in HCG administration day, implantation rate and clinical pregnancy rate were higher but not statistically significant Method In this study, 40 patients who were candidates for ART were randomly selected. In all patients long luteal protocol was used for ovulation induction. After down regulation with GnRH agonist, FSH alone was administered for 40 normoresponder patients until the dominant follicle reached 14 mm, then patients were randomly divided into two groups: Group 1 (n=20) with standard long protocol (GnRH agonist ) and r-FSH alone, Group 2 (n=20) with standard long protocol (GnRH agonist) and r-FSH with r-LH. Results were statistically analyzed and compared in two groups. Conclusion In our study administration of rLH in late follicular phase there was no beneficial effect on outcomes in young women with mean age of 31 years. Maybe a greater sample size should be used to see the effects more accurately; also it is possible that rLH becomes useful in older patients.